Patents by Inventor Hiroshi Nagase

Hiroshi Nagase has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11011745
    Abstract: To provide an anode mixture configured to, when used in an all-solid-state battery, decrease the resistance of the all-solid-state battery and increase the charging performance of the all-solid-state battery, wherein the anode mixture is an anode mixture for an all-solid-state battery comprising an anode comprising an anode mixture layer; wherein the anode mixture contains a first anode active material and a second anode active material; and wherein a difference between a reaction potential of the first anode active material with respect to lithium metal and a reaction potential of the second anode active material with respect to lithium metal, is 1.0 V or more.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: May 18, 2021
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventor: Hiroshi Nagase
  • Patent number: 10995092
    Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and Rio, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: May 4, 2021
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi Nagase, Eriko Nakata, Masaaki Hirose, Isao Ooi
  • Publication number: 20210078955
    Abstract: The present invention aims to provide a novel low-molecular-weight compound showing an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as described in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.
    Type: Application
    Filed: December 11, 2018
    Publication date: March 18, 2021
    Applicants: University of Tsukuba, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hiroshi NAGASE, Tsuyoshi SAITOH, Masashi YANAGISAWA, Yoko IRUKAYAMA
  • Publication number: 20210040094
    Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R9 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
    Type: Application
    Filed: October 13, 2020
    Publication date: February 11, 2021
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
  • Patent number: 10916808
    Abstract: One aspect of the present invention provides a sulfide solid-state battery provided with: a negative electrode collector containing copper; a negative electrode mix layer disposed on the negative electrode collector, and containing a negative electrode active material; a positive electrode mix layer containing a positive electrode active material; a sulfide solid electrolyte layer sandwiched between the negative electrode mix layer and the positive electrode mix layer, and having a protruding portion that protrudes from a peripheral edge of the negative electrode mix layer and extends up to the negative electrode collector; and a reference electrode disposed in the protruding portion.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: February 9, 2021
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventor: Hiroshi Nagase
  • Publication number: 20200099044
    Abstract: To provide an anode mixture configured to, when used in an all-solid-state battery, decrease the resistance of the all-solid-state battery and increase the charging performance of the all-solid-state battery, wherein the anode mixture is an anode mixture for an all-solid-state battery comprising an anode comprising an anode mixture layer; wherein the anode mixture contains a first anode active material and a second anode active material; and wherein a difference between a reaction potential of the first anode active material with respect to lithium metal and a reaction potential of the second anode active material with respect to lithium metal, is 1.0 V or more.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 26, 2020
    Applicant: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventor: Hiroshi NAGASE
  • Publication number: 20200079775
    Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and Rio, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
    Type: Application
    Filed: July 19, 2019
    Publication date: March 12, 2020
    Applicant: NIPPON CHEMIPHAR CO., LTD
    Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
  • Patent number: 10525015
    Abstract: The present invention relates to a nalfurafine-containing percutaneous absorption patch having a support, a drug layer and a control layer which are laminated successively, wherein the drug layer contains at least one kind of a drug selected from the group consisting of nalfurafine and a salt thereof, and capable of maintaining a given level of drug skin permeation amount without permeation of an excess amount of the drug through the skin in a short time even when applied to the skin in which the horny cell layer and the like are damaged and the skin barrier is insufficient.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: January 7, 2020
    Assignee: UNIVERSITY OF TSUKUBA
    Inventors: Hiroshi Nagase, Makiko Tada, Megumi Yashima, Takeshi Saiki
  • Publication number: 20190328725
    Abstract: The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exhibits an opioid ? receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid ? receptor related diseases (for example, headache) can be treated or prevented.
    Type: Application
    Filed: September 15, 2017
    Publication date: October 31, 2019
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
  • Publication number: 20190334209
    Abstract: One aspect of the present invention provides a sulfide solid-state battery provided with: a negative electrode collector containing copper; a negative electrode mix layer disposed on the negative electrode collector, and containing a negative electrode active material; a positive electrode mix layer containing a positive electrode active material; a sulfide solid electrolyte layer sandwiched between the negative electrode mix layer and the positive electrode mix layer, and having a protruding portion that protrudes from a peripheral edge of the negative electrode mix layer and extends up to the negative electrode collector; and a reference electrode disposed in the protruding portion.
    Type: Application
    Filed: April 26, 2019
    Publication date: October 31, 2019
    Applicant: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventor: Hiroshi NAGASE
  • Patent number: 10442802
    Abstract: A morphinan derivative represented by the following general formula (I): (wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc., R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group, Y binds to a carbon atom as a ring-constituting atom of R2, R3, R4, and R5 represent hydrogen; hydroxy, etc., R6a and R6b represent hydrogen, etc., R7 and R8 represent hydrogen, etc., R9 and R10, which are the same or different, represent hydrogen, etc., X represents O or CH2, and Y represents C(?O)), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: October 15, 2019
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
  • Patent number: 10396346
    Abstract: A method of manufacturing a negative electrode for a nonaqueous electrolyte secondary battery, the method includes mixing negative electrode active material particles and ferroelectric particles with each other to form first composite particles in which the ferroelectric particles are attached to the negative electrode active material particles; mixing the first composite particles and a binder with each other to form granulated particles; applying pressure to an aggregate of the granulated particles to form a sheet-shaped negative electrode mixture layer; and arranging the negative electrode mixture layer on a main surface of a negative electrode current collector foil.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: August 27, 2019
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Koji Kinoshita, Hiroshi Nagase, Tatsuya Hashimoto
  • Patent number: 10377763
    Abstract: The purpose of the present invention is to provide a compound useful as a prophylactic or therapeutic agent for various diseases and symptoms related to orexin receptors, and a medical usage of the same. The present invention provides a morphinan derivative represented by the general formula (I) below or a pharmaceutically acceptable acid addition salt thereof, the morphinan derivative having excellent selectivity for and antagonism against orexin receptors and excellent therapeutic and prophylactic effects on drug dependence, and an orexin receptor antagonist and a therapeutic or prophylactic agent for drug dependence each containing it as an active ingredient.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 13, 2019
    Assignee: UNIVERSITY OF TSUKUBA
    Inventors: Hiroshi Nagase, Naoshi Yamamoto, Yoko Irukayama, Tsuyoshi Saitoh, Masashi Yanagisawa, Yasuyuki Nagumo
  • Patent number: 10361424
    Abstract: A method of manufacturing a negative electrode for a nonaqueous electrolyte secondary battery, the method includes mixing negative electrode active material particles and ferroelectric particles with each other to form first composite particles in which the ferroelectric particles are attached to the negative electrode active material particles; mixing the first composite particles and a binder with each other to form granulated particles; applying pressure to an aggregate of the granulated particles to form a sheet-shaped negative electrode mixture layer; and arranging the negative electrode mixture layer on a main surface of a negative electrode current collector foil.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: July 23, 2019
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Koji Kinoshita, Hiroshi Nagase, Tatsuya Hashimoto
  • Patent number: 10351522
    Abstract: The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: July 16, 2019
    Assignees: UNIVERSITY OF TSUKUBA, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hiroshi Nagase, Masashi Yanagisawa, Tsuyoshi Saitoh, Noriki Kutsumura, Yoko Irukayama
  • Publication number: 20180369161
    Abstract: The present invention relates to a nalfurafine-containing percutaneous absorption patch having a support, a drug layer and a control layer which are laminated successively, wherein the drug layer contains at least one kind of a drug selected from the group consisting of nalfurafine and a salt thereof, and capable of maintaining a given level of drug skin permeation amount without permeation of an excess amount of the drug through the skin in a short time even when applied to the skin in which the horny cell layer and the like are damaged and the skin barrier is insufficient.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 27, 2018
    Applicant: UNIVERSITY OF TSUKUBA
    Inventors: Hiroshi NAGASE, Makiko TADA, Megumi YASHIMA, Takeshi SAIKI
  • Patent number: 10141602
    Abstract: A problem of the present invention is to provide a lithium solid battery in which generation of short-circuits caused by dendrite is inhibited. The present invention solves the problem by providing a lithium solid battery comprising a solid electrolyte layer having a sulfide glass containing an ion conductor which has a Li element, a P element and a S element, and having an average pore radius calculated by mercury press-in method being 0.0057 ?m or less.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: November 27, 2018
    Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Takamasa Ohtomo, Hisatsugu Yamasaki, Hiroshi Nagase
  • Publication number: 20180305369
    Abstract: The purpose of the present invention is to provide a compound useful as a prophylactic or therapeutic agent for various diseases and symptoms related to orexin receptors, and a medical usage of the same. The present invention provides a morphinan derivative represented by the general formula (I) below or a pharmaceutically acceptable acid addition salt thereof, the morphinan derivative having excellent selectivity for and antagonism against orexin receptors and excellent therapeutic and prophylactic effects on drug dependence, and an orexin receptor antagonist and a therapeutic or prophylactic agent for drug dependence each containing it as an active ingredient.
    Type: Application
    Filed: October 28, 2016
    Publication date: October 25, 2018
    Applicant: UNIVERSITY OF TSUKUBA
    Inventors: Hiroshi NAGASE, Naoshi YAMAMOTO, Yoko IRUKAYAMA, Tsuyoshi SAITOH, Masashi YANAGISAWA, Yasuyuki NAGUMO
  • Publication number: 20180179151
    Abstract: The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 28, 2018
    Applicants: UNIVERSITY OF TSUKUBA, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hiroshi NAGASE, Masashi YANAGISAWA, Tsuyoshi SAITOH, Noriki KUTSUMURA, Yoko IRUKAYAMA
  • Patent number: 9963460
    Abstract: A morphinan derivative represented by the following formula (I), a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a medicament, an analgesic and an antipruritic drug including the same as an active ingredient: wherein R is selected from hydrogen and C1-6 alkyl, and n represents an integer of 0 to 2.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: May 8, 2018
    Assignees: University of Tsukuba, Nippon Chemiphar Co., Ltd.
    Inventors: Hiroshi Nagase, Naoshi Yamamoto